Category: BIIB – Biogen Inc. Common Stock

Biogen Inc (NASDAQ: BIIB) reported fairly solid third-quarter results Wednesday, sending its shares higher. Against this backdrop, an analyst at SVB Leerink said the key to outperformance for the company is a positive regulatory ruling on its controversial Alzheimer’s treatment candidate aducanumab.The Biogen Analyst: Marc Goodman maintained an Outperform rating on Biogen with a $342 price target. The Biogen Takeaways: Notwithstanding the better-than-expected headline numbers, a faster-than-expected decline in sales of spinal muscular dystrophy drug Spinraza and overly optimistic consensus estimate for the multiple sclerosis drug Tecfidera are cause of concern, Goodman said in a note.Vumerity, also used to treat multiple sclerosis, is unlikely to break above the $500-million mark in sales given physician feedback and the generic Tecfidera competition, the analyst said. Biogen’s pipeline, though growing is filled with more high risk-reward, early stage assets, making it difficult for investors to realize the value until true proof-of-concept studies are revealed, he said. Related Link: The Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer Conference As far as Biogen is concerned, it is all about aducanumab and the upcoming Nov. 6 Adcom meeting, Goodman said. View more earnings on BIIB”And our positive view on that outcome considerably outweighs these concerns mentioned above, all of which are fairly understood by the investment community and reflected with such a low P/E multiple for the stock.” If aducanumab gets to the market, investor perception of Biogen’s pipeline will become more positive, as the drug candidate creates a nice “halo effect” around the company’s high-risk, high-reward R&D strategy, the analyst said. Takeaways On Aducanumab From Earnings Call: The FDA could give its verdict on aducanumab earlier than the March 7 PDUFA date, as the Adcom meeting was also scheduled early, Goodman said, citing Biogen management. Among regulatory submissions outside of the U.S., Biogen said it has submitted a marketing authorization approval to the European Medicines Agency and is working on preparing for a regulatory submission in Japan, the analyst said. The company is making commercial preparations in the U.S. in anticipation of a positive verdict, while also working on launch readiness activities in Europe and Japan, he said. Following the third-quarter results, SVB Leerink increased its 2020 EPS estimate for Biogen from $32.45 to $33.35. BIIB Price Action: Biogen shares were down 1.93% at $263.73 at last check Thursday. Related Link: Price Over Earnings Overview: Biogen Latest Ratings for BIIB DateFirmActionFromTo Oct 2020Credit SuisseMaintainsOutperform Oct 2020WedbushMaintainsNeutral Oct 2020Morgan StanleyMaintainsOverweight View More Analyst Ratings for BIIB View the Latest Analyst Ratings See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * The Daily Biotech Pulse: Prothena Progress In Parkinson’s Disease Pipeline, Fast Track For Xeris, Biogen Earnings * Why Morgan Stanley Is Buying The Dip In Eli Lilly(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

BIIB earnings call for the period ending September 30, 2020.

Biogen earnings and sales fell less than expected in the third quarter, but the biotech giant cut its full-year revenue and earnings guidance, and BIIB stock fell in early trading Wednesday.

The biotech sector was in focus as Biogen’s (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron’s (REGN) Ebola drug gets FDA approval.

Drugmaker Biogen’s third-quarter results feel the effect of generic versions of its multiple sclerosis treatment.

Dr. Kanika Monga, Rheumatologist in Houston, Texas, joins Yahoo Finance’s Akiko Fujita to break down the latest coronavirus developments, as cases across the U.S. continue to spike.

Biogen earnings and sales fell less than expected in the third quarter, but the biotech giant cut its full-year revenue and earnings guidance, and BIIB stock fell in early trading Wednesday.

Biogen and Idec merged in 2003, combining forces to market Biogen’s multiple sclerosis drug Avonex and Idec’s cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen’s MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

The biotech sector was in focus as Biogen’s (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron’s (REGN) Ebola drug gets FDA approval.